vs
Side-by-side financial comparison of CMB.TECH NV (CMBT) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
CMB.TECH NV is the larger business by last-quarter revenue ($592.8M vs $339.0M, roughly 1.7× HAEMONETICS CORP). CMB.TECH NV runs the higher net margin — 32.3% vs 13.2%, a 19.1% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (-2.7% vs -34.6%).
CMB.TECH, before October 2024 known as Euronav, is a crude oil tanker transport company, which consists of VLCCs, Suezmaxes and FSOs.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
CMBT vs HAE — Head-to-Head
Income Statement — Q4 FY2024 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $592.8M | $339.0M |
| Net Profit | $191.2M | $44.7M |
| Gross Margin | — | 59.7% |
| Operating Margin | 46.4% | 19.9% |
| Net Margin | 32.3% | 13.2% |
| Revenue YoY | -34.6% | -2.7% |
| Net Profit YoY | -63.3% | 19.3% |
| EPS (diluted) | $1.01 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $339.0M | ||
| Q3 25 | — | $327.3M | ||
| Q2 25 | — | $321.4M | ||
| Q1 25 | — | $330.6M | ||
| Q4 24 | $592.8M | $348.5M | ||
| Q3 24 | — | $345.5M | ||
| Q2 24 | — | $336.2M | ||
| Q4 23 | $905.9M | $336.3M |
| Q4 25 | — | $44.7M | ||
| Q3 25 | — | $38.7M | ||
| Q2 25 | — | $34.0M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | $191.2M | $37.5M | ||
| Q3 24 | — | $33.8M | ||
| Q2 24 | — | $38.4M | ||
| Q4 23 | $521.2M | $31.2M |
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% | ||
| Q4 23 | — | 52.9% |
| Q4 25 | — | 19.9% | ||
| Q3 25 | — | 17.9% | ||
| Q2 25 | — | 16.8% | ||
| Q1 25 | — | 21.6% | ||
| Q4 24 | 46.4% | 16.9% | ||
| Q3 24 | — | 15.0% | ||
| Q2 24 | — | 11.8% | ||
| Q4 23 | 63.4% | 13.7% |
| Q4 25 | — | 13.2% | ||
| Q3 25 | — | 11.8% | ||
| Q2 25 | — | 10.6% | ||
| Q1 25 | — | 17.5% | ||
| Q4 24 | 32.3% | 10.8% | ||
| Q3 24 | — | 9.8% | ||
| Q2 24 | — | 11.4% | ||
| Q4 23 | 57.5% | 9.3% |
| Q4 25 | — | $0.95 | ||
| Q3 25 | — | $0.81 | ||
| Q2 25 | — | $0.70 | ||
| Q1 25 | — | $1.17 | ||
| Q4 24 | $1.01 | $0.74 | ||
| Q3 24 | — | $0.66 | ||
| Q2 24 | — | $0.74 | ||
| Q4 23 | $2.58 | $0.61 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $38.9M | $363.4M |
| Total DebtLower is stronger | $2.6B | $1.2B |
| Stockholders' EquityBook value | $1.2B | $911.5M |
| Total Assets | $3.9B | $2.5B |
| Debt / EquityLower = less leverage | 2.20× | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $363.4M | ||
| Q3 25 | — | $296.4M | ||
| Q2 25 | — | $292.9M | ||
| Q1 25 | — | $306.8M | ||
| Q4 24 | $38.9M | $320.8M | ||
| Q3 24 | — | $299.3M | ||
| Q2 24 | — | $344.4M | ||
| Q4 23 | $429.4M | $194.0M |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | $930.7M | — |
| Q4 25 | — | $911.5M | ||
| Q3 25 | — | $849.2M | ||
| Q2 25 | — | $882.3M | ||
| Q1 25 | — | $820.8M | ||
| Q4 24 | $1.2B | $906.9M | ||
| Q3 24 | — | $878.9M | ||
| Q2 24 | — | $905.4M | ||
| Q4 23 | $2.4B | $943.3M |
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | $3.9B | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B | ||
| Q4 23 | $3.4B | $2.2B |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | 2.20× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | 0.39× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $204.4M | $93.6M |
| Free Cash FlowOCF − Capex | — | $87.2M |
| FCF MarginFCF / Revenue | — | 25.7% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | 1.07× | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | — | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $93.6M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $17.4M | ||
| Q1 25 | — | $116.6M | ||
| Q4 24 | $204.4M | $43.8M | ||
| Q3 24 | — | $48.8M | ||
| Q2 24 | — | $-27.4M | ||
| Q4 23 | $435.8M | $-540.0K |
| Q4 25 | — | $87.2M | ||
| Q3 25 | — | $106.3M | ||
| Q2 25 | — | $13.6M | ||
| Q1 25 | — | $100.9M | ||
| Q4 24 | — | $35.2M | ||
| Q3 24 | — | $39.4M | ||
| Q2 24 | — | $-33.1M | ||
| Q4 23 | $65.6M | $-15.2M |
| Q4 25 | — | 25.7% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 30.5% | ||
| Q4 24 | — | 10.1% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | — | -9.8% | ||
| Q4 23 | 7.2% | -4.5% |
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 1.7% | ||
| Q4 23 | 40.9% | 4.4% |
| Q4 25 | — | 2.09× | ||
| Q3 25 | — | 2.88× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 2.01× | ||
| Q4 24 | 1.07× | 1.17× | ||
| Q3 24 | — | 1.44× | ||
| Q2 24 | — | -0.71× | ||
| Q4 23 | 0.84× | -0.02× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMBT
Segment breakdown not available.
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
